<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Jiangnan_Background skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Jiangnan/Background</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="Jnav"><DIV class="Jnavtitle"><A href="https://2018.igem.org/Team:Jiangnan/Safety">Safety</A></DIV><DIV class="Jnavtitle"><A href="https://2018.igem.org/Team:Jiangnan/Hardware">Hardware</A></DIV><DIV class="Jnavtitle" onmouseover="Jnavshow(this)" onmouseleave="Jnavhide(this)"><A href="https://2018.igem.org/Team:Jiangnan/Team">Team</A><DIV class="Jnavdrag"><UL><LI><A href="https://2018.igem.org/Team:Jiangnan/Team">Team Members</A></LI><LI><A href="https://2018.igem.org/Team:Jiangnan/Attributions">Attribution</A></LI><LI><A href="https://2018.igem.org/Team:Jiangnan/Collaborations">Collaboration</A></LI></UL></DIV></DIV><DIV class="Jnavtitle" onmouseover="Jnavshow(this)" onmouseleave="Jnavhide(this)"><A href="https://2018.igem.org/Team:Jiangnan/Human_Practices">Human Practice</A><DIV class="Jnavdrag"><UL><LI><A href="https://2018.igem.org/Team:Jiangnan/Human_Practices">Overview</A></LI><LI><A href="https://2018.igem.org/Team:Jiangnan/Silver">Silver</A></LI><LI><A href="https://2018.igem.org/Team:Jiangnan/Entrepreneurship">Gold</A></LI><LI><A href="https://2018.igem.org/Team:Jiangnan/Public_Engagement">Public Engagement</A></LI><LI><A href="https://2018.igem.org/Team:Jiangnan/Entrepreneurship">Entrepreneurship</A></LI></UL></DIV></DIV><DIV class="Jnavtitle"><A href="https://2018.igem.org/Team:Jiangnan/Model">Model</A></DIV><DIV class="Jnavtitle" onmouseover="Jnavshow(this)" onmouseleave="Jnavhide(this)"><A href="https://2018.igem.org/Team:Jiangnan/Notebook">Notebook</A><DIV class="Jnavdrag"><UL><LI><A href="https://2018.igem.org/Team:Jiangnan/Notebook">Lab Book</A></LI><LI><A href="https://2018.igem.org/Team:Jiangnan/Protocol">Protocol</A></LI></UL></DIV></DIV><DIV class="Jnavtitle" onmouseover="Jnavshow(this)" onmouseleave="Jnavhide(this)"><A href="https://2018.igem.org/Team:Jiangnan">Project</A><DIV class="Jnavdrag"><UL><LI><A href="https://2018.igem.org/Team:Jiangnan/Background">Background</A></LI><LI><A href="https://2018.igem.org/Team:Jiangnan/Design">Design</A></LI><LI><A href="https://2018.igem.org/Team:Jiangnan/Demonstrate">Demonstration</A></LI><LI><A href="https://2018.igem.org/Team:Jiangnan/Results">Result</A></LI><LI><A href="https://2018.igem.org/Team:Jiangnan/Parts">Part</A></LI></UL></DIV></DIV></DIV><DIV style="background-color: #f0ebea;width:100%"><H3 style="position: absolute; top: 1em; z-index: 1;margin-top: 1em;text-align: center; color: white;width: 100%">Background</H3><DIV class="row " style="margin: 0 auto;"><DIV class="col s8 offset-s2"><P>Vaccine has been considered as one of the most cost-effective public health solution which could be used to prevent a large varieties of diseases. However, several factors such as high cost, unstable quality, weak supervision have been considerably limiting the development of the vaccine industry. Jiangnan team is thus motivated to reduce the cost of vaccine production through establishing a suspension cell line with self-owned intellectual for rapid production of a broad spectrum of viruses using synthetic biology approaches.</P></DIV><DIV class="col s8 offset-s2"><P>We do not have any biosafety issue as we do not work with human viruses but focus on animal vaccine at the current stage which do not impose any risk to the lab or environment.</P></DIV><DIV class="col s8 offset-s2"><H4 style="text-align: center;">Reference</H4><P>1. Merten O W. Introduction to animal cell culture technology—past, present and future [J]. Cytotechnology, 2006, 50(1-3): 1.
		2. Tapia F, Vázquez-Ramírez D, Genzel Y, et al. Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production [J]. Appl Microbiol Biotechnol, 2016, 100(5): 2121-2132.
		3. Vlecken D H W, Pelgrim R P M, Ruminski S, et al. Comparison of initial feasibility of host cell lines for viral vaccine production [J]. Journal of Virological Methods, 2013, 193(1): 28-41.</P></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>